表紙
市場調查報告書

全球獸醫疫苗市場:成長,趨勢,預測

Veterinary Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 704738
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
全球獸醫疫苗市場:成長,趨勢,預測 Veterinary Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 114 Pages
簡介

本報告提供全球獸醫疫苗市場相關調查,彙整市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介等相關資訊。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 推動市場的要素
  • 阻礙市場的要素
  • 波特的五力分析

第5章 市場區隔

  • 各疫苗
    • 家禽
    • 其他
  • 各寵物疫苗
  • 各技術
    • 活病毒疫苗
    • 去活化疫苗
    • 類毒素疫苗
    • 重組疫苗
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭環境

  • 企業簡介
    • Zoetis Animal Healthcare
    • Merck & Co.
    • Virbac SA
    • Hester Biosciences Ltd
    • Elanco
    • Boehringer Ingelheim Animal Health GmbH
    • Ceva Sante Animale
    • Phibro Animal Health Corp.
    • HIPRA

第7章 市場機會與未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52917

Market Overview

The veterinary vaccines market was valued at USD 7,226 million in 2018 and is expected to register a CAGR of about 5.78%, during the forecast period, 2019-2024. The veterinary vaccines market is expected to be driven by technological innovations in vaccines, increasing awareness regarding animal health, increasing investments by government bodies and associations, increased demand for animal protein, including milk, meat, eggs, and fish, and increased expenditure on healthcare for companion animals.

Anthrax is one of the most common livestock diseases in the world. According to a report published by WHO (World Health Organization), although national programs have resulted in the containment of anthrax globally, it is still prevalent, primarily due to the lack of experience of the most recent generations of veterinarians in identifying and reporting the disease and the discontinuation of vaccination against the disease.

From January to April 2015, disease reports from countries in North and West Africa, the Middle East, and East, South, and Southeast Asia mainly included foot-and-mouth disease (FMD) and H5N1 highly pathogenic avian influenza (HPAI) outbreaks, which are the two major transboundary animal diseases of economic concern, globally. This period was also characterized by the continued global spread of various avian influenza (AI) subtypes, regional spread of H5N1 HPAI in West Africa, and continued regional spread of lumpy skin disease (LSD) in the Middle East. Continuations of the ongoing regional epidemics of Ebola in West Africa and the Middle East respiratory syndrome coronavirus (MERS-CoV) in the Middle East were observed. Thus, increasing incidence of livestock diseases is the major factor driving the growth of the veterinary vaccines market, as these diseases can be eradicated with the periodic use of vaccines for animals.

Other factors which are driving the veterinary vaccines market growth are rising incidence of zoonotic diseases and initiatives taken by government agencies, animal associations, and leading players.

Scope of the Report

The veterinary vaccines market has been segmented based on vaccine type, technology, and geography. By vaccine type, the market is divided into livestock vaccines and companion animal vaccines. By technology, the market is divided into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other technologies.

Key Market Trends

Canine Vaccines Sub-segment holds the Largest Market Share in the Companion Vaccine Segment

Veterinary vaccines are used primarily for livestock, as they suffer from various diseases, such as bluetongue virus, foot-and-mouth disease (FMD), and rabies, among others. However, canine vaccine, which is a sub-segment of the companion animal vaccines segment, dominated the market in terms of revenue. Vaccination has long been a principal point of canine practice since it is one of the safest and most cost-effective means of infectious disease prevention. The rapid proliferation of companion animal vaccines, advancement in diagnostic services and vaccine technology, and concerns over vaccine safety have contributed to the strong growth of the canine vaccine segment. Moreover, the market is being positively affected by evolving vaccine protocols with continuous changing patterns of diseases and pet population.

North America Dominates the Market by Value and Asia-Pacific is expected to grow with the Highest Growth Rate

North America held the largest share of USD 3,191.72 million in 2018 and is expected to reach USD 4,491.75 million by 2024, at an estimated CAGR of 5.86%, over the forecast period. However, due to the increasing adoption of veterinary vaccines for quality food products and better animal health, Asia-Pacific is projected to experience rapid growth, while recording a CAGR of 6.10% during the forecast period.

Competitive Landscape

The veterinary vaccines market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence, and are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition, due to a rapidly expanding market size, fueled by rising concerns over food safety and the increasing adoption of companion animals.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Livestock Diseases
    • 4.2.2 Increasing Incidence of Zoonotic Diseases
    • 4.2.3 Initiatives by Government Agencies, Animal Associations, and Leading Players
  • 4.3 Market Restraints
    • 4.3.1 High Storage Costs for Vaccines
    • 4.3.2 Shortage of Veterinarians and Skilled Farm Workers
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Vaccine Type
    • 5.1.1 Livestock Vaccines
      • 5.1.1.1 Bovine Vaccines
      • 5.1.1.2 Poultry Vaccines
      • 5.1.1.3 Porcine Vaccines
      • 5.1.1.4 Other Livestock Vaccines
    • 5.1.2 Companion Animal Vaccines
      • 5.1.2.1 Canine Vaccines
      • 5.1.2.2 Feline Vaccines
      • 5.1.2.3 Equine Vaccines
  • 5.2 By Technology
    • 5.2.1 Live Attenuated Vaccines
    • 5.2.2 Inactivated Vaccines
    • 5.2.3 Toxoid Vaccines
    • 5.2.4 Recombinant Vaccines
    • 5.2.5 Other Technologies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Zoetis Animal Healthcare
    • 6.1.2 Merck & Co.
    • 6.1.3 Virbac SA
    • 6.1.4 Hester Biosciences Ltd
    • 6.1.5 Elanco
    • 6.1.6 Boehringer Ingelheim Animal Health GmbH
    • 6.1.7 Ceva Sante Animale
    • 6.1.8 Phibro Animal Health Corp.
    • 6.1.9 HIPRA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS